KEKhadizha M. Emirova

Khadizha M. Emirova

*This is an algorithmically generated author record based on publicly available information.

Khadizha M. Emirova has a total of 114 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Current Guidelines for the Management of Patients with Urinary Tract Infection

    by Alexander A. Baranov, Roman S. Kozlov, Leyla S. Namazova-Baranova, Irina V. Andreeva, Elena A. Vishneva, Nurali Z. Zokirov, Tatiana V. Kulichenko, Tea V. Margieva, Evgeniy V. Dovgan, Olga U. Stetsyuk, et al.

    Urinary tract infections in children are among the most common bacterial infections in pediatric practice. The article discusses in detail their clinical manifestations, diagnostic criteria, including laboratory and instrumental research methods, as well as treatment strategies, including the choice of antibacterial therapy and the duration of treatment. Special attention is paid to the prevention of recurrence of urinary tract infections. These clinical guidelines are based on the latest scientific research and international standards, which makes them an important tool for pediatricians and other medical professionals involved in the treatment of children with this pathology. The application of these guidelines in practice helps to improve the quality of medical care and reduce the risk of complications associated with urinary tract infections.

  • GENETIC AND PHENOTYPIC PROFILE OF PEDIATRIC PATIENTS WITH ATYPICAL HEMOLYTIC-UREMIC SYNDROME

    by Kh.M. Emirova, O.V. Krasko, T.Yu. Abaseyeva, T.E. Pankratenko, A.L. Muzurov, V.K. Vakhitov, M.K. Soboleva, A.L. Shavkin, I.N. Lupan, V.V. Albot, et al.

    Atypical hemolytic uremic syndrome (aHUS) is a life-threatening disease caused by dysregulation of the alternative complement pathway as a result of mutations in complement genes or the formation of antibodies (AB) to some of the complement factors. Identification of the gene mutations incidence and the corresponding phenotypic features in pediatric patients with aHUS in Russia is aimed at improving the diagnosis and prognosis of the disease as well as treatment tactics planning for patient management. The purpose of this research was to determine the patterns of progression, prognosis and outcomes of aHUS in children depending on their genetic profile. Materials and methods used: the Article represents data from a retro- and prospective analyses of the characteristics of the course of aHUS in 172 children depending on their genetic profile performed in Jan. 2012-Feb. 2022. The sporadic form of aHUS was diagnosed after exclusion of the other forms of thrombotic microangiopathy (TMA), the familial form (in cases with the familial records), the acquired (CFH-Ab HUS) in cases with AB increase to factor H. AutoAb against factor H was determined by enzyme-linked immunosorbent assay (ELISA-VIDITEST anti-complement factor H). The search for mutations (n=167) was carried out using Next-generation Sequencing (NGS) and Sanger sequencing methods. Results: the sporadic form of aHUS was diagnosed in 96.9% of cases, familial in 3.1% and CFH-Ab HUS in 23.8%. The genetic nature of aHUS was confirmed in 53.4% of cases. Pathogenic mutations were detected in 8.6% of cases, probably pathogenic in 42.8% and those with unclear clinical significance in 46.8%. The complement genes mutations were detected in 88.5% of cases and mutations of genes not related to the complement system (ADAMTS13, DGKE, INF2) in 11.5%. The most frequently identified mutations were in the CFH (17.1%), C3 (12.9%) and CD46 (12.9%) genes and less frequently in CFI (7.1%), THBD (5.7%), CFHR5 (5.7%) and CFB (1.4%). In children with CFH-Ab HUS, the CFHR1/CFHR3 deletion was detected in 87.8% of cases, including in 19.4% in combination with mutations of unknown clinical significance. Multiple organ failure syndrome had developed in 77.8% of cases in children with pathogenic/probably pathogenic mutations, in 85.3% in patients with mutations of unknown clinical significance, in 91.8% in patients without mutations and in 83.3% in patients with CFHR1/CFHR3 deletion. Chronic kidney disease (CKD) stages 3 to 5 in sporadic/familial aHUS, regardless of genetic profile, had counted for 14.5% and 16.7% in CFH-Ab HUS. Lethal outcome occurred in 4.3% of cases in the presence of mutations, in 4.9% in the absence of mutations and in 2.8% in cases of CFHR1/CFHR3 deletion. Relapses of aHUS prior to the Eculizumab treatment had developed more often in the presence of CFHR1/CFHR3 mutations and deletion in comparison with children without mutations (31.4% v. 13.1%, p=0.0313 and 44.4% v. 13.1%, p= 0.004). Relapse of aHUS after discontinuation of the Eculizumab therapy had developed in 16.4% of cases. Risk factors for the relapse of aHUS were as follows: patient’s age above 12 months old at the time of the development of aHUS, severe arterial hypertension in the acute period, the use of Eculizumab at the fourth week after the onset of the disease and/or later, recurrent course of aHUS and the presence of CKD prior to the start of the Eculizumab therapy. Conclusion: The genetic profile of patients does not determine the severity and outcome of aHUS though it does affect the relapse rate. The prognosis and survival of patients with aHUS are determined by the severity of the acute period and the timeliness of the complement blocking therapy management.


  • Atypical hemolytic-uremic syndrome associated with antibodies to factor H

    by Kh.M. Emirova, Moscow Saint Vladimir Moscow City Children'S Clinical Hospital, T.E. Pankratenko, V.K. Vakhitov, O.M. Orlova, O.O. Chernysheva, A.L. Muzurov, Moscow Russian Medical Academy For Continuous Professional Education, D.A. Kudlay, O.V. Zaitseva, et al.

    Atypical hemolytic-uremic syndrome (aHUS) is an ultra-rare life-threatening disease from the group of thrombotic microangiopathies (TMA) with genetic predisposition factors associated with uncontrolled activation of the alternative complement pathway. In 10% of cases aHUS is acquired and associated with antibodies to factor H (CFH-Ab-aHUS), among which 90% of cases are also determined by a deficiency of plasma proteins related to factor H (CFHR). Information on the course, therapeutic approaches and outcomes of CFH-Ab-aHUS varies Worldwide and is presented by series of clinical observations. The purpose of the research was to determine the patterns of the course and outcomes of CFH-Ab-aHUS to substantiate methods of effective treatment and improve prognosis. Methods used: retro- and prospective analysis of the course and outcomes of CFH-Ab-aHUS in 43 patients in Jan. 2010-Feb. 2022. The sample is continuous. In the development of microangiopathic hemolytic anemia (MAHA), thrombocytopenia and acute kidney injury (AKI), the diagnosis of CFH-Ab-aHUS was established after exclusion of other forms of TMAs and determination of immunoglobulin class G (IgG) in serum against factor H by enzyme-linked immunosorbent assay (ELISA-VIDITEST anti-complement factor H, Czech Republic). In 41 cases molecular genetic study by NGS (next generation sequencing) for aHUS panel and Sanger sequencing were performed. Results: the incidence of CFH-Ab-aHUS was 20.6% among all cases of aHUS. In 88.4% of children the disease debuted at the age of above 4 y/o. It was associated with a trigger (infections, vaccination, trauma, etc.) in 76.7% of cases. The median (Me) level of antibodies to factor H was 12400 [4187; 22181] AU/ml, which was more than 8 times higher than the normal upper limit. The acute period was characterized by the development of the TMA triad (MAGA, thrombocytopenia, AKI) in 100%, hemorrhagic syndrome (69.8%), arterial hypertension (69.8%), C3 consumption (77.8%) and dysfunction of more than 2 systems (83.7%). Neoliguric form of AKI was diagnosed in 44.2%, cardiac involvement in 65.1%, CNS in 55.8%, GI in 51.2%, pulmonary in 23.3%, and visual organ in 16.3% of cases. CFHR1/CFHR3 deletions were found in 87.8% (36/41) of cases (77.8% homozygous/ 22.2% heterozygous). Relapses were noted in 34.9%. Remission of CFH-Ab-aHUS was achieved in 11.6% of cases using plasma therapy and immunosuppressants, in 88.4% - with complement-blocking therapy (eculizumab). The outcome of the disease was characterized by the development of arterial hypertension (65.1%), CKD (60.5%), hypertrophic (25.6%) and dilated cardiomyopathy (16.3%). Conclusion: thus, in the Russin pediatric population with aHUS, every fifth child is diagnosed with CFH-Ab-aHUS associated with a risk of recurrence in every third child. The most important components of the management of patients with CFH-Ab-aHUS are its timely diagnosis and initiation of pathogenetic therapy (plasma therapy with immunosuppressants/eculizumab).


  • Homocysteine, folic acid and vitamin B12 in children with chronic kidney disease

    by T.E. Pankratenko, Moscow Regional Research and Clinical Institute (MONIKI), Kh.M. Emirova, A.L. Muzurov, S.A. Mstislavskaja, T.Ju. Abaseeva, G.A. Generalova, N.V. Shironina, M.V. Petrova

  • Factor H-related proteins in the pathogenesis of atypical hemolytic-uremic syndrome

    by Russian University of Medicine, Kh. M. Emirova, O. O. Chernysheva, S. A. Mstislavskaya, O. V. Zaitseva, V. K. Vakhitov, Kazan State Medical University, T. P. Makarova, D. A. Kudlay, Sechenov First Moscow State Medical University, et al.

    Atypical hemolytic-uremic syndrome (aHUS) is a rare disease of the group of thrombotic microangiopathies caused by hyperactivation of an alternative pathway of the complement system. One of the mechanisms of aHUS development is the change in the functional activity of proteins of the factor H (FH) family. We analyzed the available data on the influence of factor H protein family on aHUS development. A total of 43 studies published in 2003-2021, including 41 foreign ones, were reviewed. PubMed, Web of Science, Scopus, еLibrary, Google Scholar databases were searched using keywords: aHUS, factor H, factor H-like protein, factor H-related proteins (FHRs). Priority was given to the results of randomized controlled trials, systematic reviews with meta-analysis. Duplicate articles were excluded. Based on the analysis results, conclusions were drawn that disruption of C3b subunit inactivation as a result of changes in the functional activity of FH family proteins mediates the formation of a membrane-attacking complex. Among the mechanisms of FH, FHR1, and FHR3 inhibition are genetic aberrations (missense mutations, reading frame shift), formation of hybrid proteins, and synthesis of autologous antibodies. Other mechanisms of alternative pathway hyperactivation include decreased concentration or complete absence of FH, FHR1, FHR3, and FHR4 as a result of deletion of 1q31.3 fragments or formation of hybrid proteins. The change in the FH functional activity is also possible due to autoinactivation or competitive inhibition when the FHRs concentration increases.

  • Predictors of unfavorable prognosis of atypical hemolytic-uremic syndrome in children

    by Russian University of Medicine, Kh. M. Emirova, St. Vladimir Children’s Clinical Hospital, O. M. Orlova, V. K. Vakhitov, Kazan State Medical University, E. M. Chichuga, Voronezh State Medical University named after N. N. Burdenko, O. V. Zaitseva, A. L. Muzurov, et al.

    Atypical hemolytic-uremic syndrome (aHUS) is an ultra-rare disease based on the development of complement-mediated thrombotic microangiopathy, which has an unfavorable prognosis in its natural course. The purpose — to determine predictors of unfavorable prognosis of aHUS in children. Material and methods. 70 patients (aged 2.5 months — 16 years) were examined at the debut of aHUS and 54 in the catamnesis (1–6 years). The activity of metalloproteinase ADAMTS13 was determined in all children in the acute period by the FRET method. The peculiarities of the course and outcomes of the disease were analyzed. Results. 62.9% of children had decreased ADAMTS13 activity. ADAMTS13 deficiency (57.2 vs 15.6%) was associated with prolonged thrombocytopenia (p = 0.03), development of anuric acute kidney injury (p = 0.0005), increased risk of anuria (OR 8.4; 95% CI 2.2–32.1) with the need for dialysis (OR 5.25; 95% CI 1.77–15.57). In the catamnesis group, 61.1% of cases had CKD, 53.7% had proteinuria, and 38.9% had arterial hypertension. The development of CKD directly correlated with CNS damage (rpb = 0.32, p = 0.02), duration of anuria (R = 0.74, p = 0.001), thrombocytopenia (R = 0.5, p = 0.0009), duration of dialysis (R = 0.45, p = 0.008) and late start of complement-blocking therapy with eculizumab (rpb = 0.54, p = 0.0004). CКD C2-C5 in the distant catamnesis (3–6 years) developed in children who had thrombocytopenia > 10 days at the debut of aНUS (p = 0.0005), anuria > 7 days (p = 0.03) and needed dialysis > 10 days (р = 0.02). Conclusion. ADAMTS13 activity deficiency is associated with a more severe course of acute аHUS episode, but does not affect the long-term prognosis. The risk of developing CKD is associated with the severity of acute aHUS. To improve the prognosis of renal and overall survival of patients with aHUS, long-term monitoring of the condition and preventive measures aimed at ensuring long-term remission are necessary.


  • Open Access

    The Role of the Complement System in the Pathogenesis of Infectious Forms of Hemolytic Uremic Syndrome

    by Piotr P. Avdonin, Maria S. Blinova, Galina A. Generalova, Khadizha M. Emirova, Pavel V. Avdonin

    Hemolytic uremic syndrome (HUS) is an acute disease and the most common cause of childhood acute renal failure. HUS is characterized by a triad of symptoms: microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. In most of the cases, HUS occurs as a result of infection caused by Shiga toxin-producing microbes: hemorrhagic Escherichia coli and Shigella dysenteriae type 1. They account for up to 90% of all cases of HUS. The remaining 10% of cases grouped under the general term atypical HUS represent a heterogeneous group of diseases with similar clinical signs. Emerging evidence suggests that in addition to E. coli and S. dysenteriae type 1, a variety of bacterial and viral infections can cause the development of HUS. In particular, infectious diseases act as the main cause of aHUS recurrence. The pathogenesis of most cases of atypical HUS is based on congenital or acquired defects of complement system. This review presents summarized data from recent studies, suggesting that complement dysregulation is a key pathogenetic factor in various types of infection-induced HUS. Separate links in the complement system are considered, the damage of which during bacterial and viral infections can lead to complement hyperactivation following by microvascular endothelial injury and development of acute renal failure.


  • Open Access

    A Moderate Decrease in ADAMTS13 Activity Correlates with the Severity of STEC-HUS

    by Khadizha M. Emirova, Olga M. Orlova, Ekaterina M. Chichuga, Alexander L. Muzurov, Piotr P. Avdonin, Pavel V. Avdonin

    Atypical hemolytic uremic syndrome (HUS) develops as a result of damage to the endothelium of microvasculature vessels by Shiga toxin produced by enterohemorrhagic Escherichia coli (STEC-HUS). STEC-HUS remains the leading cause of acute kidney injury (AKI) in children aged 6 months to 5 years. The pathomorphological essence of the disease is the development of thrombotic microangiopathy (TMA). One of the key causes of TMA is an imbalance in the ADAMTS13–von Willebrand factor (vWF)–platelet system. The goal of the work was to clarify the role of a moderate decrease in ADAMTS13 activity in the pathogenesis of STEC-HUS. The activity of ADAMTS13 was determined in 138 children (4 months–14.7 years) in the acute period of STEC-HUS and the features of the course of the disease in these patients were analyzed. The study revealed a decrease in the activity and concentration of ADAMTS13 in 79.8% and 90.6% of patients, respectively. Measurements of von Willebrand factor antigen content and the activity of von Willebrand factor in the blood plasma of part of these patients were carried out. In 48.6% and 34.4% of cases, there was an increase in the antigen concentration and the activity of the Willebrand factor, respectively. Thrombocytopenia was diagnosed in 97.8% of children. We have demonstrated that moderately reduced ADAMTS13 activity correlates with the risk of severe manifestations of STEC-HUS in children; the rate of developing multiple organ failure, cerebral disorders, pulmonary edema, and acute kidney injury with the need for dialysis increases. It is assumed that reduction in ADAMTS13 activity may serve as a predictor of disease severity.


  • COMPREHENSIVE APPROACH TO DIAGNOSIS AND THE TREATMENT TACTICS OF ATYPICAL HEMOLYTIC UREMIC SYNDROME ASSOCIATED WITH A MUTATION IN THE CFH GENE: A CLINICAL CASE

    by Kh.M. Emirova, Moscow Saint Vladimir Moscow City Children'S Clinical Hospital, I.N. Lupan, Chelyabinsk Chelyabinsk City Children'S Clinical Hospital No. 1, Chelyabinsk Chelyabinsk Oblast Regional Children'S Clinical Hospital, A.Y. Pishchalnikov, A.M. Volyansky, D.S. Vasilkova, L.V. Glukhova, D.A. Kudlay, et al.

    The atypical hemolytic uremic syndrome (aHUS) is an ultra-rare disease with a genetically determined dysregulation of the alternative complement pathway, which leads to the development of thrombotic microangiopathy. The application of the targeted therapy in Russia has changed the natural course of the disease since 2012: from death of a patient to achieving a long-term remission of the aHUS. The authors report the clinical case of the aHUS associated with a heterozygous mutation in CFH gene c.2850G>T (p.Gln950His) in a 2 years and 2 months old pediatric patient. The difficulty in diagnosing of the aHUS was the lack of specific laboratory criteria confirming the diagnosis as well as the presence of a diarrheal prodrome at the onset. The diagnosis has been made on the basis of the development of microangiopathic hemolytic anemia, thrombocytopenia, acute kidney injury and the exclusion of other forms of thrombotic microangiopathy. The treatment of the patient in accordance with the clinical guidelines for the management of patients with this nosology proved to be effective and led to a stable remission of the aHUS, which also confirmed the correctness of the diagnosis. The described clinical case observation is of interest to pediatrician physicians and nephrologists. The important factors in the management of such patients are the timely diagnosis of the aHUS along with the initiation of complement-inhibiting Eculizumab therapy.